- •Preface
- •Contents
- •Contributors
- •1 Introduction
- •1.1 Historical Background
- •1.2 Pitfalls in Diagnosis and Methodology
- •1.3 Methods to Assess Disease Activity
- •1.4 Summary
- •References
- •2.1 Introduction
- •2.4 Pearls of Wisdom
- •References
- •3.1 Background: Overall Approach to Patient Care
- •3.1.1 Pearl
- •3.1.2 Pearl
- •3.2 Diagnosis Criteria and Laboratory Tests
- •3.2.1 Myth
- •3.2.2 Pearl
- •3.2.3 Myth
- •3.2.4 Myth
- •3.2.5 Pearl
- •3.2.6 Pearl
- •3.2.7 Pearl
- •3.3 Myths and Pearls About Clinical Presentations
- •3.3.1 Pearl
- •3.3.2 Myth
- •3.3.3 Pearl
- •3.3.4 Pearl
- •3.3.5 Pearl
- •3.3.6 Pearl
- •3.3.7 Pearl
- •3.3.8 Pearl
- •3.3.9 Pearl
- •3.3.10 Pearl
- •3.3.11 Pearl
- •3.3.12 Pearl
- •3.3.13 Myth
- •3.3.14 Pearl
- •3.3.15 Pearl
- •3.3.16 Myth
- •3.4 Myths and Pearls About Pathogenesis
- •3.4.1 Myth
- •3.4.2 Pearl
- •3.4.3 Pearl
- •3.4.4 Myth
- •3.4.5 Pearl
- •3.5 Myths and Pearls About Treatment
- •3.5.1 Myth
- •3.5.2 Pearl
- •3.5.3 Pearl
- •3.5.4 Pearl
- •3.5.5 Pearl
- •3.5.6 Pearl
- •3.5.7 Pearl
- •References
- •4.1 Background and Overview
- •4.1.1 Need for Written Information
- •4.1.2 Use of Internet as a Method to Provide Information
- •4.1.3 Patient Access to Computers
- •4.1.4 Types of Information Supplied to Patients and Referring Physicians
- •4.2.1 Background: The Confusion Surrounding Criteria for Autoimmune Disorders
- •4.2.5 Criteria for Fibromyalgia
- •4.3 Laboratory Results for ANA Often Drive Clinical Diagnosis
- •4.5 Status of Biologic Drugs in SS Patients
- •4.6 Ocular Treatment
- •4.6.2 Blepharitis
- •4.7 Therapy of Oral Manifestations
- •4.7.1 Prevention of Dental Caries
- •4.7.2 Oral Candida Prevention and Treatment
- •4.8 Summary
- •References
- •5.1 Introduction
- •5.4 Outcome Measures in SS
- •5.4.1 Outcome Measures in SS: A Brief History
- •5.6 Outcome Measures in SS: The Italian Study
- •References
- •6.1 Introduction
- •6.2 Benign Lymphoepithelial Lesion in Salivary Glands
- •6.3.1.2 Ectopic Germinal Center Formation
- •6.3.1.3 Clinical Implications of Ectopic Germinal Center Formation
- •6.4 Late Breaking Update
- •References
- •7.1 Conventional Radiographs
- •7.1.1 Sialography
- •7.2 Computer Tomography
- •7.3 Ultrasound
- •7.4 Magnetic Resonance Imaging
- •7.5 Nuclear Medicine
- •7.5.1 Scintigraphy
- •7.6 Comparison of Nuclear Medicine, Ultrasound, and MRI
- •References
- •8.1 Introduction
- •8.2 Evidence Supporting a Genetic Component in SS
- •8.4 Lessons from SLE and Other Autoimmune Diseases
- •8.5 Genes Implicated in SS
- •8.7 Insights from Genomic and Proteomic Studies
- •8.8 Conclusion
- •References
- •9.1 Introduction
- •9.2.4 Antibodies to Nuclear Protein NA14
- •9.3.1 Initiation Phase
- •9.3.2 Recognition Phase
- •9.3.3 Establishment Phase: Autoreactive T and B Lymphocytes Dysregulation and Aberrant Cytokines Production
- •9.3.5 Effector Phase
- •References
- •10.1 Introduction
- •10.2.1 Ro/La RNP Particles
- •10.2.3 The Ro60 Autoantigen
- •10.2.4 The Ro52 Autoantigen
- •10.2.5 The Multifunctional Chaperone Calreticulin
- •10.4.2 Early Epitope Recognition in Autoimmune Diseases and Epitope Spreading
- •References
- •11.2 Acinar Cell
- •11.3 Neuropeptides
- •11.3.1 Acinotrophic Neurogenic Stimuli
- •11.4 Sex Steroids
- •11.4.1 Steroidogenesis in Adrenal Glands
- •11.4.2 Regulation of the Adrenal Steroidogenesis
- •11.4.4 Peripheral Intracrine Synthesis of Sex Steroids
- •11.4.5 Intracrine Sex Steroids Production in pSS and sSS
- •11.4.7 Putative Mechanism of Action of the Intracrine Processing Defect
- •11.5.1 General Histopathology
- •11.5.2 T Lymphocytes
- •11.5.3 B Lymphocytes
- •11.5.4 Chemokines
- •11.5.5 Adhesion Molecules
- •11.5.6 Cytokines
- •References
- •12.1 Background
- •12.2 Incidence, Symptomatic Presentation, and Impact on Quality of Life
- •12.3 Diagnostic Screening Examination
- •12.4 Overview of Dry Eye Management
- •12.4.1 Dry Eyes Deserve Respect and Careful Monitoring
- •12.4.2 Four Levels of Severity Differentiation
- •12.4.2.1 Level 1
- •12.4.2.2 Level 2
- •12.4.2.3 Level 3
- •12.4.2.4 Level 4
- •12.5.2 General Guidelines for the Dry Eye Patient
- •12.6 Additional Types of Therapy
- •12.7 Moisture Preservation and Oral Medications
- •12.7.2 Punctal Plugs
- •12.8 Oral Medications and Supplements
- •12.8.1 Dietary Fatty acids (Flaxseed Oil) and Dry Eyes
- •12.8.2 Oral Medications
- •12.9 Complications Associated with Ophthalmologic Cosmetic Procedures
- •12.10 Summary
- •References
- •13.1 Introduction
- •13.2 The Lacrimal Functional Unit (LFU)
- •13.3 The General Role of the LFU in Normal and Pathological Situation
- •13.4 Innervation of the Lacrimal Functional Unit
- •13.5 Efferent Structures
- •13.5.1 Lacrimal Glands
- •13.5.2 Goblet Cells
- •13.5.3 Meibomian Glands
- •13.6 Maintenance of the Lacrimal Functional Unit
- •13.6.1 Hormonal
- •13.6.2 Immunological
- •13.8 The Normal Ocular Surface Environment
- •13.9 The Makeup of the Tear Film
- •13.9.1 Hydrated Mucin Gel
- •13.9.3 Aqueous Components
- •13.10 The Pathophysiology of Dry Eye
- •13.10.1 Loss of Hormonal Support
- •13.10.2.1 Afferent Arm
- •13.10.2.2 Efferent Arm
- •13.11 Loss of Ocular Surface Homeostasis
- •13.11.1 Alterations of the Mucin, Lipid, and Aqueous Composition
- •13.11.2 Mucins
- •13.11.3 Lipids
- •13.12 The Ocular Surface Immunosuppressive Environment
- •13.14 Late-Breaking Additions
- •References
- •14.1 Saliva in Oral Health and Disease
- •14.1.1 Saliva in Dental and Mucosal Defense
- •14.1.2 Assessment of Oral Dryness
- •14.1.2.2 Objective Measurements of Hyposalivation
- •14.2 Saliva as a Diagnostic Fluid
- •14.2.1 Biomarker Analyses in Saliva
- •14.3 Complications of Oral Dryness
- •14.3.1 Management of Xerostomia
- •14.3.2 Caries Preventive Measures
- •14.3.2.3 Dietary Advice
- •14.3.2.4 The Time Factor
- •References
- •15.1.1 Endothelial Cells
- •15.1.2 Epithelial Cells
- •15.1.3 T cells
- •15.1.4 B cells
- •15.2 Mechanisms Mediating Salivary Gland Dysfunction
- •15.2.1 Acinar Cell Innervation and Humoral Immunity
- •15.2.3 Fluid Movement in the Salivary Glands and Aquaporins
- •15.3.1 Environmental Factors
- •15.3.2 Secondary Signals
- •15.3.3 Apoptosis, Autoantigens, and Potential Danger Signals in the Salivary Glands
- •15.3.4 Immunoregulation
- •15.3.5 B-cell-Activating Factor
- •15.3.6 Hormones
- •15.3.7 Microchimerism
- •References
- •16.1 Introduction
- •16.2 Diagnosis
- •16.3 Head and Neck Manifestations
- •16.3.1 Ophthalmic
- •16.3.2 Oral
- •16.3.3 Otologic
- •16.3.4 Rhinologic
- •16.3.5 Laryngeal
- •16.3.6 Esophageal
- •16.3.7 Thyroid
- •16.3.8 Neurological
- •16.4 Treatment
- •16.5 Conclusion
- •16.6 Patient Handout
- •References
- •17.1 Introduction
- •17.2 Cutaneous/Dermatologic Manifestations
- •17.4 Endocrinopathic/Pancreatic Manifestations
- •17.4.1 Hypothyroidism
- •17.4.2 Adrenal
- •17.4.3 Pancreas
- •17.5 Pulmonary Manifestations
- •17.5.1 Interstitial Pneumonitis
- •17.6.1 Pericarditis
- •17.6.2 Autonomic Manifestations
- •17.6.3 Congenital Heart Block
- •17.6.4 Accelerated Atherosclerosis
- •17.7 Gastrointestinal Manifestations
- •17.8 Hepatic and Pancreatic Manifestations
- •17.9 Renal/Urological Manifestations
- •17.10 Hematologic Manifestations
- •17.11 Obstetrical/Gynecological Manifestations
- •17.12 Vasculitis
- •17.12.1 CNS Arteritis in the SS Patient
- •17.13 Differential Diagnosis of Extraglandular Manifestations of SS
- •17.13.1 Medications and Other Metabolic Disorders
- •17.14 Manifestations and Differential Diagnosis in the Pediatric Population
- •17.15 Summary
- •17.16 Late-Breaking Updates
- •References
- •18.1 Introduction
- •18.2 Treatment and Management of Cutaneous Manifestations
- •18.2.1 Treatment of Dry Skin
- •18.3 Arthralgia/Arthritis
- •18.4.1 Chronic Cough
- •18.5 Renal Manifestations
- •18.5.1 Interstitial Nephritis
- •18.5.1.1 Glomerular Disease
- •18.6 Gastrointestinal Manifestations
- •18.6.1 Mesenteric Vasculitis
- •18.6.2 Primary Biliary Cirrhosis
- •18.7 Urologic
- •18.8 Therapeutic Management of Obstetrical/Gynecological Manifestations
- •18.9 Special Precautions at the Time of Surgery
- •18.10 Vaccinations in the SS Patient
- •18.11 Summary
- •18.12 Late-Breaking Updates
- •References
- •19.1 Introduction
- •19.3.1 Fatigue
- •19.3.2 Musculoskeletal
- •19.3.4 Gastrointestinal Manifestations
- •19.3.5 Liver Involvement
- •19.3.6 Lung Involvement
- •19.3.7 Kidney Involvement
- •19.3.8 Neurologic Involvement
- •19.3.9 Hematologic Involvement
- •19.4 Conclusions
- •References
- •20.1 Introduction
- •20.2 Diagnosis
- •20.3 Staging and Evaluation of Treatment Response
- •20.4 Treatment
- •20.5 Summary/Pearls
- •References
- •21.1 Introduction
- •21.2 What Is Fatigue?
- •21.3 Potential Causes of Fatigue in pSS
- •21.3.1 Biological
- •21.3.1.1 Cytokines
- •21.3.1.2 Neuroendocrine
- •21.3.1.3 Sleep
- •21.3.2 Psychosocial
- •21.3.2.1 Depression
- •21.3.2.2 Fibromyalgia
- •21.4 Measurement of Fatigue and Other Extraglandular Symptoms
- •21.6 Potential Approaches to Treatment of Fatigue and Other Extraglandular Symptoms
- •21.7 Measurement of Dryness (Sicca) Symptoms
- •21.8 Data from Existing Clinical Studies Addressing Dryness in pSS
- •21.9 Conclusion: Clinical Trial Outcomes
- •References
- •22.1 Introduction
- •22.2 Clinical Evaluation of Neurological Findings in SS
- •22.3.1 Role of Cell-Mediated Immunity
- •22.3.2 The Role of Antibodies Associated with Neurological Manifestations of SS
- •22.4 Investigations
- •22.4.1 Neurophysiology
- •22.4.2 Autonomic Studies
- •22.4.3 MR Imaging of the Spinal Cord
- •22.5 Peripheral Clinical Manifestations
- •22.6 Painful Sensory Neuropathies
- •22.6.1 Differential Diagnosis
- •22.7 Sensory Ataxic Neuropathy
- •22.7.1 Differential Diagnosis
- •22.8 Neuromuscular Weakness
- •22.8.1 Differential Diagnosis
- •22.9 Neuromuscular Pain
- •22.9.1 Differential Diagnosis
- •22.10 Autonomic Neuropathy
- •22.10.1 Differential Diagnosis
- •22.11 Trigeminal Neuropathy and Other Cranial Neuropathies
- •22.12 Central Nervous System Manifestations
- •22.12.2 Cognitive Impairment
- •22.12.3 Movement Disorders
- •22.12.4 Aseptic meningitis and Meningoencephalitis
- •22.12.5 Other Neurological Disorders
- •22.13 Investigations of Central Nervous System Manifestations
- •22.13.1 Serology
- •22.13.2 Spinal Fluid
- •22.13.4 Nuclear Brain Imaging Studies
- •22.13.5 Cerebral Angiography
- •22.14 The Puzzling Neurological Manifestations of Fibromyalgia
- •22.15 Interpretation of ANA in the Patient with Neurological Symptoms
- •22.16 Treatment
- •22.16.1 Peripheral Nervous System Treatment: Overview
- •22.16.2 Painful Sensory Neuropathies
- •22.16.3 Ataxic Neuropathy
- •22.16.4 Motor and Sensory Neuropathies
- •22.16.5 Central Nervous System Treatment
- •22.16.6 Side Effects of Immunosuppressive Therapy
- •22.17 Summary of Special Points to Neurologists
- •22.17.3 Relationship of Neurological Symptoms to Sicca Manifestations
- •22.18 Summary for Rheumatologists
- •References
- •23.1 Introduction
- •23.3.1 Labial Minor Salivary Gland Biopsy
- •23.3.2 Sialography
- •23.4 The Application of a Bite Guard
- •References
- •24.1 Introduction
- •24.2 How to Provide the Essential Tear Components to the Ocular Surface
- •24.3 Use of Autologous Serum Eye Drops for the Treatment of Dry Eye
- •24.4 Ongoing Research with Autologous Serum Eye Drops
- •24.5 Preparation of Autologous Serum Eye Drops
- •24.8 Conclusion
- •References
- •References
- •27.1 A Disease of Antiquity in Ancient China
- •References
- •References
- •References
- •30.1 Introduction
- •30.2 Evaluation of Systemic Features of Primary SS
- •30.2.4 Comparisons of Systemic Disease Activity Scores
- •30.3.1 The SSI: Sicca Symptoms Inventory
- •30.4 Conclusion
- •References
- •31.1 Clinical Practice Guidelines
- •31.2 Clinical Trials Consortium
- •31.3 Professional Education and Awareness
- •31.4.1 Rheumatology Working Group
- •31.4.2 Ocular Working Group
- •31.4.3 Oral Working Group
- •31.4.5 Facilitator for Both Initiatives
- •32.1 Introduction
- •32.2 For Which Patients Should Biological Therapy Be Considered?
- •32.7 BAFF Inhibition
- •32.8 Interferon Inhibition
- •32.9 Gene Therapy
- •32.10 Other Targets for Biologic Therapy
- •32.11 Conclusions and Future Directions
- •References
- •33.1 Overview of the Pathogenesis of pSS
- •33.1.1 Initial Steps
- •33.1.1.1 Breach of Self-tolerance
- •33.1.1.2 Activation of Innate Immunity and Interferon Pathways
- •33.1.1.4 Regulation of BAFF Secretion
- •33.1.1.6 Other Cytokines, Chemokines, and Adhesion Molecules Are Involved in the Pathogenesis of the Disease
- •33.1.3 Glandular Hypofunction Rather Than Glandular Destruction
- •33.2 Emerging Therapies
- •33.2.1 Prerequisite for the Development of New Drugs in pSS
- •33.2.1.1 Disease Activity Score
- •33.2.1.2 Selection of Patients
- •33.2.3.1 Inhibition of the Triggering Factors of IFN Activation
- •33.2.3.2 IFN Blockade
- •33.2.3.3 Antagonists of BAFF and APRIL
- •33.2.3.4 B-cell Depletion
- •33.2.3.5 Other B-cell-Targeted Therapy: Other Anti-CD20 and Anti-CD22
- •33.3 Other Therapeutic Perspectives
- •33.3.1 Inhibition of Other Cytokines and Chemokines
- •33.3.3 Gene Therapy
- •33.4 Conclusion
- •References
- •34.1 Introduction
- •34.5 Conclusion
- •References
- •Index
342 |
A.G. Tzioufas and H.M. Moutsopoulos |
|
|
19.3.8 Neurologic Involvement
Peripheral neurologic involvement is found in 5Ð10% of patients with pSS. In contrast, the presence of central nervous system involvement is a matter of debate with descriptions ranging from ÒundetectableÓ to Òquite commonÓ and a variety of reported clinical manifestations, including multiple sclerosis-like disease, stroke, transverse myelitis, or psychiatric manifestations [37, 38]. Because of the rarity of cases, controlled therapeutic trials are lacking. However, immunosuppressive treatments with pulse intravenous cyclophosphamide, in combination with steroids, are currently considered the treatment strategy of choice [39]. The early institution of treatment during the course of the disease is crucial and mostly beneÞcial [40]. Azathioprine, methotrexate, mycophenolate mofetil, or cyclosporine may be used in the failure or intolerance of cyclophosphamide. In the case of progressing neurologic symptoms, IVIg and plasmapheresis may be considered [39].
The peripheral, primary sensory neuropathies usually respond poorly to treatment (reviewed in Ref. [9]); however, stabilization of symptoms, spontaneous or after treatment, is often seen [41]. In multiple mononeuropathies, nerve biopsy frequently reveals vasculitis, which may explain the efÞcacy of steroids and immunosuppressive drugs. In contrast, steroids appear to have a poor effect in axonal polyneuropathies [38]. IVIg has recently demonstrated beneÞt [42Ð44], even in cases resistant to treatment or long-standing sensory neuropathy [45, 46]. A recent work has shown that IVIg improves SS-related dysautonomia, by anti-idiotypic antibodies neutralizing serum IgG against the muscarinic M3 receptors [47]. Case presentations of patients with sensory neuropathy treated with plasmapheresis [48] have been reported.
19.3.9 Hematologic Involvement
Patients with pSS present with hypergammaglobulinemia and mild asymptomatic autoimmune cytopenias. Serious manifestations, such
as severe cytopenias, may occur infrequently and warrant more aggressive treatment [49]. Steroids are the Þrst-line treatment for autoimmune cytopenias with the additional steroidsparing agent azathioprine or danazol [49, 50]. Cyclophosphamide, or methotrexate, has been reported in cases of autoimmune hemolytic anemia, thrombocytopenia, and agranulocytosis, respectively [50, 51]. IVIg in combination with cyclosporine has been tried in agranulocytosis complicating pSS [51, 52].
19.4Conclusions
The systemic manifestations of pSS are observed in more than 50% of patients comprising the main factors for increased morbidity of the disease. Extraglandular manifestations are divided into periepithelial (liver, lung, and interstitial nephritis) and extraepithelial (palpable purpura, nervous system involvement, and glomerulonephritis) with the latter being the main prognostic factors for poor outcome. Their treatment remains mostly empiric and symptom-based. Current immunosuppressive therapies appear to be unable to modify the course of the disease. The association of traditional treatments with newer promising biologic agents is still an unaddressed question. To this end, well-constructed epidemiologic and basic science data are needed to move treatment of this disorder from the empiric to a more scientiÞc, etiologic approach.
References
1.Dafni UG, Tzioufas AG, Staikos P, Skopouli FN, Moutsopoulos HM. Prevalence of SjšgrenÕs syndrome in a closed rural community. Ann Rheum Dis. 1997;56:521Ð5.
2.Tzioufas AG, Voulgarelis M. Update on SjšgrenÕs syndrome autoimmune epithelitis: from classiÞcation to increased neoplasias. Best Pract Res Clin Rheumatol. 2007;21:989Ð1010.
3.Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of SjšgrenÕs syndrome. Arch Intern Med. 2004;164:1275Ð84.
4.Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality
19 Current Treatment of Extraglandular Manifestations with Disease-Modifying . . . |
343 |
of primary SjšgrenÕs syndrome. Semin Arthritis Rheum. 2000;29: 296Ð304.
5.Strombeck B, Ekdahl C, Manthorpe R, Jacobsson LT. Physical capacity in women with primary SjogrenÕs syndrome: a controlled study. Arthritis Rheum. 2003;49:681Ð8.
6.Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classiÞcation of primary SjogrenÕs syndrome. Arthritis Rheum. 2002; 46:741Ð7.
7.Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary SjogrenÕs syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262Ð9.
8.Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of SjšgrenÕs syndrome. Nat Clin Pract Rheumatol. 2006;2:252Ð61.
9.Thanou-Stavraki A, James JA. Primary SjogrenÕs syndrome: current and prospective therapies. Semin Arthritis Rheum. 2008;37:273Ð92.
10.Barendregt PJ, Visser MR, Smets EM, et al. Fatigue in primary SjšgrenÕs syndrome. Ann Rheum Dis. 1998;57:291Ð5.
11.dÕElia HF, Rehnberg E, Kvist G, Ericsson A, Konttinen Y, Mannerkorpi K. Fatigue and blood pressure in primary SjogrenÕs syndrome. Scand J Rheumatol. 2008;37:284Ð92.
12.MÕRad S, Ben Miled K, Makni S, et al. JaccoudÕs arthropathy in primary SjšgrenÕs syndrome with benign hypergammaglobulinaemic purpura. Eur J Med. 1993;2:373Ð5.
13.Fox RI, Kang HI. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993;2:S9Ð12.
14.Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol. 1993;20: 803Ð8.
15.Dawson LJ, CaulÞeld VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary SjogrenÕs syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology 2005;44:449Ð55.
16.Lakhanpal S, Duffy J, GrifÞng WL, Conn DL, Luthra HS. SjogrenÕs syndrome: treatment with D- penicillamine and hydroxychloroquine. J Rheumatol. 1985;12:1028Ð9.
17.Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary SjogrenÕs syndrome with hydroxychloroquine. Am J Med. 1988;85:62Ð7.
18.Kruize AA, Hene RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary SjogrenÕs syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52:360Ð4.
19.Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary SjogrenÕs syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996;5:S31Ð6.
20.Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary SjogrenÕs syndrome: its effect on salivary and serum inßammatory markers. Ann Rheum Dis. 1999;58:253Ð6.
21.Fox RI. SjogrenÕs syndrome. Lancet. 2005;366: 321Ð31.
22.Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary SjogrenÕs syndrome. Clin Exp Rheumatol. 1996;14:555Ð8.
23.Skopouli FN, Talal A, Galanopoulou V, et al. RaynaudÕs phenomenon in primary SjšgrenÕs syndrome. J Rheumatol. 1990;17:618Ð20.
24.Garcia-Carrasco M, Sis— A, Ramos-Casals M, et al. RaynaudÕs phenomenon in primary SjšgrenÕs syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol. 2002;29:726Ð30.
25.Volter F, Fain O, Mathieu E, Thomas M. Esophageal function and SjšgrenÕs syndrome. Dig Dis Sci. 2004;49:248Ð53.
26.Ford CN. Evaluation and management of laryngopharyngeal reßux. JAMA 2005;294:1534Ð40.
27.Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary SjšgrenÕs syndrome. Br J Rheumatol. 1994;33:745Ð8.
28.Hatzis GS, Fragoulis GE, Karatzaferis A, Delladetsima I, Barbatis C, Moutsopoulos HM. Prevalence and long term course of primary biliary cirrhosis in primary SjšgrenÕs syndrome. J Rheumatol. 2008;35:2012Ð6.
29.Matsumoto T, Morizane T, Aoki Y, et al. Autoimmune hepatitis in primary SjogrenÕs syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary SjogrenÕs syndrome. Pathol Int. 2005;55:70Ð6.
30.Papiris SA, Maniati M, Constantopoulos SH, Roussos C, Moutsopoulos HM, Skopouli FN. Lung involvement in primary SjšgrenÕs syndrome is mainly related to the small airway disease. Ann Rheum Dis. 1999;58:61Ð4
31.Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary SjogrenÕs syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005;171:632Ð8.
32.Goules A, Masouridi S, Tzioufas AG, Ioannidis JP, Skopouli FN, Moutsopoulos HM. Clinically signiÞcant and biopsy-documented renal involvement in primary Sjšgren syndrome. Medicine 2000;79: 241Ð9
33.Pessler F, Emery H, Dai L, et al. The spectrum of renal tubular acidosis in paediatric Sjšgren syndrome. Rheumatology 2006;45:85Ð91
34.Siamopoulos KC, Mavridis AK, Elisaf M, Drosos AA, Moutsopoulos HM. Kidney involvement in primary SjšgrenÕs syndrome. Scand J Rheumatol Suppl. 1986;61:156Ð60
344 |
A.G. Tzioufas and H.M. Moutsopoulos |
|
|
35.Moutsopoulos HM, Balow JE, Lawley TJ, Stahl NI, Antonovych TT, Chused TM. Immune complex glomerulonephritis in sicca syndrome. Am J Med. 1978;64:955Ð60.
36.Linardaki G, Moutsopoulos HM. The uncertain role of immuno-suppressive agents in SjšgrenÕs syndrome. Cleve Clin J Med. 1997;64: 523Ð6.
37.Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in SjogrenÕs syndrome. Ann Rheum Dis. 2004;63:616Ð20.
38.Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjšgren syndrome: a study of 82 patients. Medicine 2004;83:280Ð91.
39.Rogers SJ, Williams CS, Roman GC. Myelopathy in SjogrenÕs syndrome: role of nonsteroidal immunosuppressants. Drugs 2004;64:123Ð32.
40.de Seze J, Delalande S, Fauchais AL, et al. Myelopathies secondary to SjogrenÕs syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. J Rheumatol. 2006;33:709Ð11.
41.Font J, Ramos-Casals M, de la Red G, et al. Pure sensory neuropathy in primary SjogrenÕs syndrome. Long-term prospective follow-up and review of the literature. J Rheumatol. 2003;30:1552Ð7.
42.Molina JA, Benito-Leon J, Bermejo F, JimenezJimenez FJ, Olivan J. Intravenous immunoglobulin therapy in sensory neuropathy associated with SjogrenÕs syndrome. J Neurol Neurosurg Psychiatry. 1996;60:699.
43.Pascual J, Cid C, Berciano J. High-dose i.v. immunoglobulin for peripheral neuropathy associated with SjogrenÕs syndrome. Neurology 1998;51:650Ð1.
44.Kizawa M, Mori K, Iijima M, Koike H, Hattori N, Sobue G. Intravenous immunoglobulin treatment
in painful sensory neuropathy without sensory ataxia associated with SjogrenÕs syndrome. J Neurol Neurosurg Psychiatry. 2006;77:967Ð9.
45.Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I. BeneÞt of IVIG for long-standing ataxic sensory neuronopathy with SjogrenÕs syndrome. Neurology 2003;60:503Ð5.
46.Wolfe GI, Nations SP, Burns DK, Herbelin LL, Barohn RJ. BeneÞt of IVIg for long-standing ataxic sensory neuronopathy with SjogrenÕs syndrome. Neurology 2003;61:873.
47.Cavill D, Waterman SA, Gordon TP. Antiidiotypic antibodies neutralize auto-antibodies that inhibit cholinergic neurotransmission. Arthritis Rheum. 2003;48:3597Ð602.
48.Chen WH, Yeh JH, Chiu HC. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with SjogrenÕs syndrome. Eur Neurol. 2001;45: 270Ð4.
49.Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary Sjogren syndrome: hematologic patterns of disease expression. Medicine 2002;81:281Ð92.
50. Schattner A, |
Friedman J, KlepÞsh A, Berrebi |
A. Immune |
cytopenias as the presenting Þnd- |
ing in primary SjogrenÕs syndrome. QJM 2000;93: 825Ð9.
51.Friedman J, KlepÞsh A, Miller EB, Ognenovski V, Ike RW, Schattner A. Agranulocytosis in SjogrenÕs syndrome: two case reports and analysis of 11 additional reported cases. Semin Arthritis Rheum. 2002;31:338Ð45.
52.Coppo P, Sibilia J, Maloisel F, et al. Primary
SjogrenÕs syndrome associated agranulocytosis: a benign disorder? Ann Rheum Dis. 2003;62: 476Ð8.
Lymphoproliferation and |
20 |
Lymphoma in Sjögren’s Syndrome |
Justin Pijpe, Hendrika Bootsma, and Gustaaf W. van Imhoff
Abstract
A multidisciplinary approach is necessary for evaluation and treatment of patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma and associated SjšgrenÕs syndrome (MALTÐSS). If asymptomatic MALT lymphoma is detected in a parotid biopsy by chance during a routine diagnostic procedure for SS, and there are no severe extraglandular manifestations of SS present, staging and treatment of MALT lymphoma may probably be deferred. In other patients with MALTÐSS both SS activity and symptoms of MALT lymphoma (e.g., large swelling, pain) should be taken into account to guide treatment. Future clinical studies in MALTÐSS patients should determine the clinical signiÞcance of asymptomatic clonal B-cell inÞltrate in patients with SS and the place of maintenance treatment with monoclonal antibodies in long-term disease control.
Keywords
SjšgrenÕs syndrome ¥ MALT lymphoma ¥ Treatment
20.1Introduction
SjšgrenÕs syndrome (SS) is a systemic autoimmune disease characterized by chronic inßammation of salivary and lacrimal glands, frequently accompanied by systemic symptoms. Five percent of patients with SS develop malignant B-cell lymphoma, 48Ð75% of which are of
J. Pijpe ( )
Department of Oral and Maxillofacial Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands; University Medical Center, Groningen, The Netherlands e-mail: j.pijpe@gmail.com
mucosa-associated lymphoid tissue (MALT)- type. These B-cell lymphomas are most frequently located in the parotid gland [1Ð3]. A recent analysis showed that SS was associated with a 6.6-fold increased risk of non-Hodgkin lymphoma, and secondary SS yielded a higher risk than the primary form [4]. Moreover, this study showed a 1,000-fold increase in relative risk of MALT lymphoma localized in the parotid glands in patients with SS. This Þnding is consistent with biological evidence of antigen-driven clonal B-cell expansions in the affected salivary glands. An immune reaction to speciÞc antigenic stimulation is also believed to play an important
R.I. Fox, C.M. Fox (eds.), Sjögren’s Syndrome, DOI 10.1007/978-1-60327-957-4_20, |
345 |
© Springer Science+Business Media, LLC 2011 |
|
346 |
J. Pijpe et al. |
|
|
Fig. 20.1 a Enlarged parotid gland in a patient with SS and MALT lymphoma. b Coronal MRI of same patient showing cystic enlarged parotid glands and bilateral lymphadenopathy
role in other MALT lymphomas, such as Helicobacter pylori in gastric MALT lymphoma,
Borrelia burgdorferi in skin, and Chlamydia trachomatis in ocular MALT lymphoma [5]. Apart from persistently enlarged parotid glands (Fig. 20.1a), the emergence of lymphoma in SS (MALTÐSS) is frequently heralded by extraglandular manifestations of SS (e.g., palpable purpura, vasculitis, renal involvement, and peripheral neuropathy). None of these features are speciÞc, but any of them should raise suspicion, particularly if accompanied by features such as monoclonal gammopathy, reduced levels of complement C4, CD4+ T lymphocytopenia, or cryoglobulinemia (Table 20.1) [6Ð10]. Ioannidis et al. demonstrated that lymphoproliferative disease was independently predicted by parotid gland enlargement, palpable purpura, and low C4 levels [7].
In general, MALT lymphoma is an indolent disease, with a reported 5-year overall survival between 86 and 95%, without signiÞcant difference in clinical course between localized and disseminated disease [12, 13]. Recurrences may involve extranodal or nodal sites and transformation into aggressive diffuse large B-cell lymphoma is rare, occurring in less than 10% of the cases [14].
The traditional Ann Arbor staging system, mainly designed for nodal lymphoma, is not very
Table 20.1 Risk factors for lymphoma development in SS [11]
•Persistent parotid gland enlargement
•Palpable purpura
•Low C3, C4
•Cryoglobulinemia
•Monoclonal paraproteinemia
•Increased β(beta)-2 microglobulin
•Lymphocytopenia
•Hypoglobulinemia
informative for patients with MALT lymphoma. For instance, involvement of multiple extranodal sites, i.e., multiple salivary glands in case of MALTÐSS, may neither reßect truly disseminated disease as in nodal lymphoma types nor confer inferior prognosis associated with stage IV disease in nodal lymphoma [5]. MALTÐSS is often localized at one or more salivary sites (usually the parotid gland[s]), but can occur also in other extranodal sites, such as the orbital adnexa and stomach [15, 16]. Dissemination of MALTÐSS is usually detected in local draining lymph nodes. Distant lymph nodes, other mucosal sites, or bone marrow is seldomly involved [17].
In our experience with the follow-up of 35 patients with MALTÐSS, 25 patients (71%) showed only localization of lymphoma in the